在雄激素剥夺治疗后VRK1水平升高通过上调YAP1表达来促进前列腺癌的进展
Yibo Meng1, Jianchao Ge1, Cheng Zhou1
1Department of Urology, The Fifth People'S Hospital of Shanghai, Fudan University, No. 801, Heqing Road, Minhang District, Shanghai, 200240, People's Republic of China.
疫苗相关激酶1 (VRK1) 通过上调YAP1.1,促进前列腺癌 (PCa) 细胞增殖和治疗耐药性. VRK1 作为预后标志物,其抑制抑制了 PCa 的生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 疫苗相关激酶1 (VRK1) 是一种氨酸-氨酸激酶,与癌细胞增殖和迁移有关.
- VRK1在前列腺癌 (PCa) 进展和治疗耐药性的特定作用尚不清楚.
研究的目的:
- 研究VRK1在前列腺癌 (PCa) 进展和治疗耐药性的作用.
- 探索VRK1,雄激素受体 (AR) 信号传递和癌细胞增殖之间的关系.
主要方法:
- 建立了与雄激素独立的PCa细胞系,并进行了转录组和蛋白质组测序.
- 分析了大型临床样本数据库,并在治疗条件下评估了VRK1-AR信号相关性.
- 在体外和体内评估VRK1对细胞增殖的影响,并通过测序和救援实验探索VRK1调节的途径.
主要成果:
- VRK1表达在进展到抗割PCa时增加,与预后不佳相关.
- VRK1是由AR信号调节的;VRK1沉默抑制了PCa细胞的增殖在体外和体内.
- VRK1通过调节对相关蛋白1 (YAP1) 来促进PCa细胞的增殖和治疗耐药性.
结论:
- VRK1作为PCa的预后标志物,受AR信号的影响.
- 由于VRK1的减少,抑制了PCa细胞的增殖.
- 升高的VRK1可以提高YAP1的调节,从而促进PCa的增殖和治疗抵抗.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
09:55All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
Published on: December 20, 2021
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
Induced Pluripotent Stem Cells
Somatic...
